Project Grant R21CA307485
Award Date 4/8/26
Completion Date 3/31/28
Dollars Obligated $399K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Kansas City, KS 66160, USA
Similar Awards
- Federal Grant Award Summary The University of Kansas Medical Center Research Institute, Inc. received a $135,951 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective September 4, 2025, with completion targeted for August 31, 2030. This award supports a research initiative focused on enhancing access to breast cancer prevention clinical trials, addressing critical gaps in patient and provider engagement across the cancer...
- Federal Grant Award Summary The University of Kansas Medical Center Research Institute, Inc. received a $135,949 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2030. This R50 Clinician Scientist Award supports the expansion of access and enrollment to precision medicine trials in Acute Myeloid Leukemia (AML). The grant addresses critical barriers to clinical trial enrollment by...
- Federal Project Grant Award Summary The University of Tennessee Health Science Center received a $658,561 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective August 7, 2025, with a completion date of July 31, 2030. This award supports research focused on targeted MDM2 (Murine Double Minute 2) degradation as an improved therapeutic strategy for triple-negative breast cancer (TNBC). The project centers on optimization and...
- Federal Grant Award Summary The National Cancer Institute awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) beginning April 1, 2026, and extending through March 31, 2031. This award supports research investigating tumor regenerative cell (TRC) populations that drive resistance to neoadjuvant therapy and metastatic recurrence in locally advanced rectal cancer (LARC). The research deliverables include genomic...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute, under its Cancer Treatment Research program (CFDA 93.395), awarded The Methodist Hospital Research Institute $403,485 in project grant funding beginning September 1, 2025, through August 31, 2027. The award supports the development of novel platinum-based polymers designed to induce robust reactive oxygen species (ROS) production with tumor-specific toxicity targeting triple-negative breast cancer (TNBC). This research addresses a...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $399,129 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2025, with a completion date of June 30, 2027. This award supports research to develop and evaluate improved cancer treatment methods through laboratory and clinical investigation. Specifically, the research leverages a DDX3 inhibitor called RK-33 to alter the metabolic tumor environment in...
- Federal Grant Award Summary Natsar Pharmaceuticals, Inc. received a $1.63 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to advance the development and commercialization of RK-33, a small molecule inhibitor targeting DDX3 (DEAD-box helicase 3) for treating triple-negative breast cancer (TNBC). The award, obligated on September 22, 2025, with a completion date of August 31, 2027, supports the continued development of this...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 project grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025 and concluding August 31, 2027. This grant funds research investigating P300/CBP (lysine acetyltransferases) as novel therapeutic targets in clear cell renal cell carcinoma (ccRCC). The research will examine the therapeutic potential of targeting P300/CBP through pharmacological...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $395,846 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2031. This award supports research into therapeutic targeting of SMARCAL1 as a synthetic lethal vulnerability in alternative lengthening of telomeres (ALT)-positive cancers, specifically IDH-mutant astrocytomas. The research focuses on...